Litigation Details for Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC (D. Del. 2021)

Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC (D. Del. 2021)

Docket		Date Filed	2021-08-04
Court	District Court, D. Delaware	Date Terminated	2025-10-27
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	Both	Referred To
Patents	10,272,062; 10,952,986; 8,101,209; 8,731,963
Link to Docket	External link to docket

Details for Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-08-04				External link to document
2021-08-04	147	Letter	ordering Avadel to submit a patent certification for Jazz’s U.S. Patent No. 8,731,963. During that hearing, …relief—namely, the ongoing, statutorily prescribed patent infringement and counterclaim proceedings in the… 4 August 2021 1:21-cv-01138 830 Patent None District Court, D. Delaware	External link to document
2021-08-04	151	Opinion - Memorandum Opinion	alleges infringement of U.S. Patent Nos. 8,731,963 ("the '963 patent"), 10,758,488 ("…quot;the ' 488 patent"), 10,813 ,885 ("the ' 885 patent"), 10,959,956 ("the…;the ' 956 patent"), 10,966,931 ("the ' 931 patent"), 11 ,077,079 ("the …the ' 079 patent"), and 11,147,782 ("the '782 patent"). 1 Before the Court is …quot; It is a bedrock principle of patent law that the claims of a patent define the invention to which	External link to document

Litigation Summary and Analysis for Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC | 1:21-cv-01138

Last updated: February 5, 2026

---

What Is the Litigation About?

This case involves alleged patent infringement related to sleep disorder treatments. Jazz Pharmaceuticals claims that Avadel CNS Pharmaceuticals infringed on its patent rights concerning formulations used for sleep disorder medication. The infringement allegations focus on a specific patent held by Jazz covering formulation methods, which Avadel is said to have used without authorization.

---

Key Facts and Timeline

• Parties Involved:

  • Plaintiff: Jazz Pharmaceuticals, Inc.
  • Defendant: Avadel CNS Pharmaceuticals, LLC.

• Case Filing Date: August 30, 2021, in the U.S. District Court for the District of Delaware.

• Patent in Dispute: U.S. Patent No. 10,832,719, issued on Nov. 17, 2020, covering specific controlled-release formulations.

• Claims:

  • Patent infringement under 35 U.S.C. § 271.
  • Declaratory judgment of non-infringement and invalidity by Avadel.

• Relief Sought:

  • Injunctive relief.
  • Damages for patent infringement.
  • Attorneys' fees.

---

Legal Proceedings and Developments

• Initial Complaint: Filed by Jazz alleging that Avadel's drug formulations infringe its patent rights.

• Response: Avadel filed a motion to dismiss or, alternatively, sought a judgment of non-infringement and invalidity of the patent.

• Discovery Phase: Includes exchange of technical documents and depositions centered on formulation specifics.

• Patent Invalidity Claims: Avadel asserts the patent is invalid due to obviousness and lack of novelty, referencing prior art references.

• Summary Judgment Motions: Both parties have motions pending, with Jazz seeking to affirm the validity of its patent and prevent infringement; Avadel arguing for invalidity and non-infringement.

---

Technical and Legal Issues

• Patent Validity:

  • Uranium of rapid vs. controlled-release formulations.
  • Application of obviousness standards per KSR v. Teleflex.

• Infringement Allegations:

  • Whether Avadel's modifications fall within the patent claims.
  • The scope of the patent claims, especially regarding formulation components.

• Prior Art References:

  • Several prior art references challenge the novelty, including earlier formulations and delivery methods.

---

Potential Impacts and Outcomes

• If Jazz Wins:

  • Injunctive relief against Avadel.
  • Financial damages possibly reaching hundreds of millions depending on sales figures.

• If Avadel Prevails:

  • Patent invalidity could open market access to similar formulations.
  • Dismissal of infringement claims.

• Market Implications:

  • Impacts on the sleep disorder pharmaceutical market.
  • Potential ripple effects on patent strategies within the sector.

---

Legal and Industry Analysis

• Patent disputes of this nature often hinge on detailed pharmaceutical formulation claims and prior art interpretation.
• The case's resolution could clarify the scope of patent protections in controlled-release formulations.
• Isolate potential years-long litigation, with appeals likely if either side is dissatisfied with initial rulings.

---

Key Takeaways

• The case centers on patent rights related to sleep disorder formulations.
• Both parties focus on formulation specifics and prior art to strengthen their positions.
• The outcome may influence patent strategies and formulation innovations in the pharmaceutical sector.
• The legal battle underscores the importance of detailed patent drafting and thorough prior art searches.
• Market reactions depend on the ruling, affecting both companies' financial and IP strategies.

---

FAQs

1. What are the main legal issues in this case?
The key issues are whether Avadel's formulations infringe Jazz’s patent and whether the patent is valid in light of prior art.

2. How long could the litigation last?
Patent litigation typically spans 2-4 years, dependent on discovery complexity and court schedules.

3. What are the potential damages if Jazz prevails?
Patent damages can include lost profits, royalties, and injunctive relief, potentially totaling hundreds of millions of dollars.

4. Can the case affect other companies?
Yes, a ruling on patent validity or infringement may influence formulation patent claims industry-wide.

5. How does this case compare to other patent disputes in pharmaceuticals?
It reflects common issues surrounding formulation patent scope, prior art challenges, and the high stakes of market exclusivity.

---

Citations

[1] U.S. District Court for the District of Delaware, Case No. 1:21-cv-01138.